Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten (MyoKardia) is a novel, oral, allosteric modulator of cardiac myosin. This therapy was specifically ...

"Women come significantly later to their cardiologists and have the same peri-procedural [alcohol septal ablation] complications and worse long-term outcomes, which are caused by their older age; ...

The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced.

Please provide your email address to receive an email when new articles are posted on . The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

"Older patients often tolerate medications poorly and younger patients may feel lethargic and tired with beta blockers and calcium channel blockers. These patients would be appropriate candidates for ...

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Hypertrophic cardiomyopathy is a genetic heart condition characterized by the thickening of the heart muscle, leading to ...

Mavacamten, an investigational allosteric modulator of cardiac myosin, has proved superior to placebo for improving symptoms and reducing or eliminating obstruction of the left ventricle in patients ...